dmab sales

Why are dmab sales so low? Reimbursement seems lame excuse. Are docs worried about onj? or increased tumour?

 

They are worried about all the ABOVE. Safety is the #1 concern. If you were a patient and you read the patient literature or what was on the internet, I'm sure you wouldn't want to use Prolia either. It's tough, I think there should have been more negociations with the FDA regarding the label and Amgen should have not been in such a rush to get it approved.

 

Think about it. I can prescribe an oral medication that has reimbursement and if the patient has a problem I can stop the medication, but with this drug once i inject it its in there for months.

Think about your average physician, which choice will they make

 

The rebound after stopping dmab is a major concern too. Bone resoprtion can be a sticking point. Too many dmab team members have left for competitors like Merck and no doubt they have been sharing the worts and underside of dmab and sales strategy. Their effect is obvious now.

 

B&B is the main problem.....Since when did PCPs started B&B an $800 injection, that too for pocket change return and in OSTEOPOROSIS

I could'nt believe GM saying in the call that " we have founf out that physicians are not going to B&B easily". DUH!! are u fuckin kidding me. How hard was that to figure out.

This was a specialist drug from the get go .....expensive, MOA, B&B, second line label, and fuckin OSTEOPOROSIS-no body gives a shit about osteo to pay that much amount for the mainstream pt population.

Plus if you are targeting PCPs, strategize to given the drug on credit and consider billing/ reimbursement/medication wastage as cost of doing business. Partner with HELIX or other specialized groups that handle B&B directly on behalf of pharma. Thats the only way Prolia can be successful.

Plus on the clinical side, kick off an extensive national thought leadership and KOL strategy to change the standard of care from (ineffective in real world) orals to injectables/infusion. Yes align yourself with Reclast and pair up against obsolete orals. With $$ and a brilliant ffective KOL/publication/communication strategy, this is doable and has been done in the past. Amgen has the $$ to pull this but brilliance/minds??...not sure.

 

Its interesting that the rebound issue is finally coming to light. I predict this will be the ultimate downfall of this drug in osteoporosis. Watch for excess fracture rate in the first six months after its stopped because of the explosive increase in bone turnover that occurs when the arrested osteoclast maturation is released from inhibition. It will take a while for this adverse event to surface, but with enough patients exposed it will eventually rear its head.

 

WTF are u talking about...downfall?? First of all, the patient who will discontinue Prolia will be on some other agent to protect from fractures any way. If on no drug and ends up with fx, then it can not be blamed on Prolia but lack of treatment. Plus even if there is this perception, that is the best thing that could happen to Prolia to ensure maximal fullfilment, continous use and better persistence profile in the real world. On the contrary, BPs are now stuck with atypical fracture risk for long term use and is now part of the actual label.

Go fuckin use your brain and try to sell some shit than predicitng downfalls,mr nobody. IDIOT!!!

 

Atypical fractures are not part of the label yet and don't know if they will be .
It is very hard to prove since you would have to do HUGE clinical trials to really show a causal relationship.
I think the above posters are right on. Prolia is a drug that got into the market a bit too late for osteoporosis. Maybe it can do better vs. Zometa but doesn't have the indication yet and will only have a short time until Zometa goes generic.

 

Thank God someone has some sense. When I picture all of you previous posters, I see a room full of whiney-ass, fat-ass, bitchy women who are jealous of some woman they know bc she's got new boobs.

Go back to your own web-site and deal with your FDA WARNING FOR AN INCREASED RISK OF ATYPICAL THIGH FRACTURES. By the way Reclast, those results from your transition trial from Fosamax were AWESOME weren't they!

I guess Prolia has new boobs! Biaaaaaaaaaaaaaaatches.

 

C;mon. Prolia sales are so anemic i'm tired of crying each night. I hope we're acquired so we can get rid of these incompent dms.

 

Exjiva(?) = Denosumab Oncology

 

Why do many of the posters print nothing but foul language? Is it a reflection of your IQ?

 

Wow the kool aid is STRONG this week!!!!! Props to Amgen fo supplying extra strong kool aid at the right time.

 

Twice the price of zometa? Who are we kidding?

 

YES cuz We are superior BITCH!!!!!

 

Are you one of those mental midgets that works in Production at ARI?

 

I wasn't talking about the atypical fractures of the thigh reported after long term BP use. I was talking about the explosive increase in bone turnover markers that hapens when this drug is stopped. Its due to a sudden loss of inhibitory effect on OC maturation that is a fundamental property of the drug's MOA. Some thought leaders are (quietly so far) of the opinion that this will result in higher risk of fractures in the first months after discontinuation because of acute, focused bone remodeling and resultant structural weakness. I agree it will take awhile for this kind of AE to become apparent, especially with the low exposed numbers so far because of poor sales. I used the atypical fracture with BP case just as an example of how this kind of problem often takes a while to become obvious.

 

If you Prolia reps don't mind, let this Reclast rep educate you for one second. Considering most of you sold Reclast at one point, some of this may sound familiar to you. If you haven't figured it out yet, Relationships are what sells medications in an overcrowded market. In the Osteo market, you are not doing well because we don't want you to do well. Your numbers are just as good as ours but they aren't better, We have 6 years of data now and you only have 3, side effects are fairly predictable with Bisph's unlike your medication, once off of the medication prolia negatively effects bone turn over, and your pricing is just too high. It doesn't really matter that you have these problems or not, because we have the relationships and we aren't letting your medication being written in our infusing offices. I imaging that Prolia is doing well in areas where a Reclast rep with relationships was hired. I don't have anything against any of you. I think Prolia is a good medication and I feel that there is huge population that could be taking this medication. The problem is, we won't let it be written, atleast not until we get laid off. Just to prove that it is a relationship market, watch what happens in my territory when I voluntarily take a sev. package. Prolia will go through the roof.

 

wow not to full of our self are we and can you get me a beer too.

 

r*****....a drug in "TODAYS" world is not sold based on freakin reps' connections (kidding me?) but most importantly other areas like.... commercial, KOL and payer strategy. NONE of which worked out well for Prolia at launch beacuse Amgen did not not have the PCP market experience. that is why we are down!!

that will change in oncology, which BTW Amgen controls all along, and where Xgeva besides being twice as expensive than zometa will kick your ass and you will have nowehere to go than to kiss you sorry ass connections.